45.37
-0.11 (-0.24%)
| Penutupan Terdahulu | 45.48 |
| Buka | 45.63 |
| Jumlah Dagangan | 620,738 |
| Purata Dagangan (3B) | 1,158,790 |
| Modal Pasaran | 9,838,075,904 |
| Harga / Pendapatan (P/E TTM) | 24.52 |
| Harga / Pendapatan (P/E Ke hadapan) | 17.89 |
| Harga / Jualan (P/S) | 5.02 |
| Harga / Buku (P/B) | 2.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Feb 2026 |
| Hasil Dividen (DY TTM) | 0.52% |
| Margin Keuntungan | 4.68% |
| Margin Operasi (TTM) | 25.89% |
| EPS Cair (TTM) | 0.430 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 12.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 41.36% |
| Nisbah Semasa (MRQ) | 3.37 |
| Aliran Tunai Operasi (OCF TTM) | 680.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 622.84 M |
| Pulangan Atas Aset (ROA TTM) | 5.75% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Qiagen N.V. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%). |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.61% |
| % Dimiliki oleh Institusi | 86.26% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (JP Morgan, 32.25%) | Beli |
| Median | 55.00 (21.23%) | |
| Rendah | 50.00 (Stifel, 10.21%) | Pegang |
| Purata | 54.80 (20.79%) | |
| Jumlah | 2 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 50.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 06 Feb 2026 | 55.00 (21.23%) | Pegang | 50.95 |
| 11 Dec 2025 | 50.00 (10.20%) | Pegang | 45.44 | |
| JP Morgan | 06 Feb 2026 | 60.00 (32.25%) | Beli | 50.95 |
| Stifel | 06 Feb 2026 | 50.00 (10.20%) | Pegang | 50.95 |
| Deutsche Bank | 22 Jan 2026 | 54.00 (19.02%) | Pegang | 54.25 |
| Barclays | 15 Dec 2025 | 55.00 (21.23%) | Beli | 45.44 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars |
| 03 Feb 2026 | Pengumuman | QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 |
| 26 Jan 2026 | Pengumuman | QIAGEN Appoints Mark Stevenson to Supervisory Board |
| 19 Jan 2026 | Pengumuman | QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast |
| 12 Jan 2026 | Pengumuman | QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth |
| 18 Dec 2025 | Pengumuman | QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |